Le proteine monoclonali possono causare alterazioni negli esami di coagulazione

AUTORI

ABSTRACT

Emostatic abnormalities in a patient treated with direct oral anticoagulants

Prothrombin Time (PT) and activated partial thromboplastin time (aPTT) are the most frequently performed coagulation test. The PT is used for assessment of clotting disorders (deficiency of factors II, V, VII and/or X) and monitoring of patients taking oral anticoagulant therapy (OAT) with vitamin K antagonist (VKAs). In patients taking VKAs, unmeasurable PT test result are frequently due to over-anticoagulation caused by excessive drug intake. The aPTT test, on the other hand, is altered in case of factorial deficiency (factors VII, IX, XI, and/or XII), presence of inhibitors (specific or non-specific) or in case of heparin contamination. Although it is widely known that monoclonal proteins are altering factors in many laboratory tests, their impact on coagulation tests can differ from patient to patient. In this work, a case of interference by monoclonal proteins on the aPTT test is described.

BIBLIOGRAFIA

1. Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol 2015;8:527-42.
2. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med 2011;12:386-92.
3. King RI, Florkowski CM. How paraproteins can affect laboratory assays; spurious results and biological effects. Pathology 2010;42:397-401.
4. Dimeski G. Interference testing. Clin Biochem 2008;29: S43-8.
5. Nanda SK, Sarangi R, Ray L, Kumar A, Padhi S. Factitious biochemical reports which are caused due to para-proteinaemia in multiple myeloma – a case report. J Clin Diag Res 2013;7:350-2.
6. Huang H, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis 2015; 26:555-9.
7. Kyle RA, Durie BGM, Rajkumar S V. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
8. Huang H, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis 2015;26:556-9.
9. Crowely MP, Quinn S, Coleman E. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. J Thromb Thrombolysis 2015;39:245-9.
10. Wu X yao, Yin Y feng, Teng J lin, et al. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: A case report. BMC Immunol 2017;18:1-4.
11. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin Mλ coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980;66:397-405.